Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer.

Burke JM, Lamm DL, Meng MV, Nemunaitis JJ, Stephenson JJ, Arseneau JC, Aimi J, Lerner S, Yeung AW, Kazarian T, Maslyar DJ, McKiernan JM.

J Urol. 2012 Dec;188(6):2391-7. doi: 10.1016/j.juro.2012.07.097. Epub 2012 Oct 22.

PMID:
23088985
2.

CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer.

Ramesh N, Ge Y, Ennist DL, Zhu M, Mina M, Ganesh S, Reddy PS, Yu DC.

Clin Cancer Res. 2006 Jan 1;12(1):305-13.

3.

Results of a phase 1 dose escalation study of intravesical TMX-101 in patients with nonmuscle invasive bladder cancer.

Falke J, Lammers RJ, Arentsen HC, Ravic M, Pozzi R, Cornel EB, Vergunst H, de Reijke TM, Witjes JA.

J Urol. 2013 Jun;189(6):2077-82. doi: 10.1016/j.juro.2012.11.150. Epub 2012 Nov 30.

PMID:
23206424
4.

A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers.

Chang J, Zhao X, Wu X, Guo Y, Guo H, Cao J, Guo Y, Lou D, Yu D, Li J.

Cancer Biol Ther. 2009 Apr;8(8):676-82. Epub 2009 Apr 22.

PMID:
19242097
5.

Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer.

Dinney CP, Fisher MB, Navai N, O'Donnell MA, Cutler D, Abraham A, Young S, Hutchins B, Caceres M, Kishnani N, Sode G, Cullen C, Zhang G, Grossman HB, Kamat AM, Gonzales M, Kincaid M, Ainslie N, Maneval DC, Wszolek MF, Benedict WF.

J Urol. 2013 Sep;190(3):850-6. doi: 10.1016/j.juro.2013.03.030. Epub 2013 Mar 15.

6.

A prospective comparative study of intravesical bacillus Calmette-Guérin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer.

Sengiku A, Ito M, Miyazaki Y, Sawazaki H, Takahashi T, Ogura K.

J Urol. 2013 Jul;190(1):50-4. doi: 10.1016/j.juro.2013.01.084. Epub 2013 Jan 30.

PMID:
23376145
7.

Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck.

Harrington KJ, Hingorani M, Tanay MA, Hickey J, Bhide SA, Clarke PM, Renouf LC, Thway K, Sibtain A, McNeish IA, Newbold KL, Goldsweig H, Coffin R, Nutting CM.

Clin Cancer Res. 2010 Aug 1;16(15):4005-15. doi: 10.1158/1078-0432.CCR-10-0196.

8.
9.

A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.

Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, Harrington KJ, James ND, Love CA, McNeish I, Medley LC, Michael A, Nutting CM, Pandha HS, Shorrock CA, Simpson J, Steiner J, Steven NM, Wright D, Coombes RC.

Clin Cancer Res. 2006 Nov 15;12(22):6737-47.

10.

Predictors of intravesical therapy for nonmuscle invasive bladder cancer: results from the surveillance, epidemiology and end results program 2003 patterns of care project.

Huang GJ, Hamilton AS, Lo M, Stein JP, Penson DF.

J Urol. 2008 Aug;180(2):520-4; discussion 524. doi: 10.1016/j.juro.2008.04.016. Epub 2008 Jun 11.

11.

Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer.

Hendricksen K, Witjes WP, Idema JG, Kums JJ, van Vierssen Trip OB, de Bruin MJ, Vergunst H, Caris CT, Janzing-Pastors MH, Witjes JA.

Eur Urol. 2008 May;53(5):984-91. doi: 10.1016/j.eururo.2007.12.033. Epub 2007 Dec 27.

PMID:
18248876
13.

A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer.

Chen CH, Yang HJ, Shun CT, Huang CY, Huang KH, Yu HJ, Pu YS.

Urol Oncol. 2012 Jul-Aug;30(4):421-7. doi: 10.1016/j.urolonc.2010.06.012. Epub 2010 Sep 25.

PMID:
20870427
15.

Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder: results of a phase I study.

Bassi PF, Volpe A, D'Agostino D, Palermo G, Renier D, Franchini S, Rosato A, Racioppi M.

J Urol. 2011 Feb;185(2):445-9. doi: 10.1016/j.juro.2010.09.073. Epub 2010 Dec 17.

PMID:
21167517
16.
17.

The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer.

Solsona E, Iborra I, Dumont R, Rubio-Briones J, Casanova J, Almenar S.

J Urol. 2000 Sep;164(3 Pt 1):685-9.

PMID:
10953125
18.

Prognostic factors in patients with carcinoma in situ treated with intravesical bacille Calmette-Guérin.

Andius P, Damm O, Holmäng S.

Scand J Urol Nephrol. 2004;38(4):285-90.

PMID:
15669587
19.

Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.

Ryan CJ, Weinberg V, Rosenberg J, Fong L, Lin A, Kim J, Small EJ.

J Urol. 2007 Dec;178(6):2372-6; discussion 2377. Epub 2007 Oct 22.

PMID:
17936834
20.

Phase I trial of granulocyte macrophage-colony stimulating factor and interleukin-4 as a combined immunotherapy for patients with cancer.

Gitlitz BJ, Figlin RA, Kiertscher SM, Moldawer N, Rosen F, Roth MD.

J Immunother. 2003 Mar-Apr;26(2):171-8.

PMID:
12616109
Items per page

Supplemental Content

Write to the Help Desk